In 2011, Patgiri et al. (2011) published the structure-based design of an α-helical peptide derived from the Sos-Protein, which is able to inhibit Sos-mediated Ras activation through interference with the Sos–Ras interaction, providing a promising lead compound for anti-cancer drugs. This evidence concerns the gene XYLT2 and cancer.